期刊文献+

溶血磷脂酸对子宫内膜癌RL-952细胞尿激酶型纤溶酶原激活剂分泌的影响 被引量:7

The effect of urokinase-type plasminogen activator secretion on endometrial carcinoma RL-952 cell by stimulating of lysophosphatidic acid
下载PDF
导出
摘要 目的探讨溶血磷脂酸(lysophosphatidic acid,LPA)对子宫内膜癌RL-952细胞尿激酶型纤溶酶原激活剂(urokinase-type plasminogen activator,uPA)分泌的影响。方法不同浓度的LPA刺激子宫内膜癌RL-952细胞24h,80μmol/LLPA刺激子宫内膜癌RL-952细胞不同时间后收集细胞上清液,采用酶联免疫吸附试验检测uPA的分泌情况,Transwell试验检测LPA对子宫内膜癌RL-952细胞体外迁移/侵袭能力的影响。结果 2、10μmol/L的LPA即可诱导子宫内膜癌RL-952细胞uPA的分泌增加,且随着LPA浓度的加大,uPA分泌量明显增多,二者呈明显的浓度依赖关系;80μmol/L的LPA作用于RL-952细胞时,随着时间的延长uPA分泌量增多,二者呈明显的时间依赖关系。并且LPA可以明显增加子宫内膜癌RL-952细胞的体外迁移/侵袭能力。结论 LPA可成为子宫内膜癌早期诊断及预后监测的分子标志物,并有望成为子宫内膜癌分子靶向治疗的靶标。 Objective To investigate the effect of urokinase-type plasminogen activator(uPA) secretion on endometrial carcinoma RL-952cell by stimulating of lysophosphatidic acid(LPA).Methods Supernatant of endo-metrial carcinoma RL-952 cells was collected after stimulating with determined concentrations of LPA for 24hours or with 80μmol/L LPA at determined times,levels of urokinase-type plasminogen activator(uPA)in these super-natant were determined by enzyme labeled immunosorbent assay(ELISA).Transwell chamber assay was used to detect the migration/invasion abilities.Results 2μmol/L,10μmol/L concentrations of LPA can induce uPA secretion,and with the concentration increasing,the uPA production increased significantly which showed obvious con-centration-dependent,and also it showed significant time-dependent.The LPA significantly increased the migration/ invasion of endometrial cancer RL-952cells.Conclusions LPA is expected to become the molecular markers,the LPA receptor and its signaling pathway is expected to become the target of the molecular therapy of endometrial cancer.
出处 《中国妇产科临床杂志》 2012年第4期291-293,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
基金 国家自然基金(C30973181)
关键词 溶血磷脂酸 子宫内膜癌 尿激酶型纤溶酶原激活剂 酶联免疫吸附试验 分子靶向治疗 lysophosphatidic acid; endometrial carcinoma; urokinase-type plasminogen activator; enzyme-linked immunosorbent assay; molecular targeted therapy
  • 相关文献

参考文献11

  • 1Sorosky JI. Endometrial cancer. Obstet Gynecol, 2008, 112 : 186 - 187.
  • 2Panupinthu N, Lee HY, Mills GB. Lysophosphatidie acid pro- duction and action: critical new players in breast cancer initia- tion and progression. Br J Cancer, 2010, 102:941 - 946.
  • 3Bese T, Barbaros M, Baykara E, et al. Comparison of total plasma lysophosphatidic acid and serum CAlxs as a tumor marker in the diagnosis and follow - up of patients with epi- thelial ovarian cancer. J Gynecol Oncol, 2010, 21: 248- 254.
  • 4Tsujino M, Fujii M, Okabe K, et al. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch, 2010, 457: 669-676.
  • 5Macchione E, Epifano O, Stefanini M, et al. Urokinase re- distribution from the secreted to the cell - bound fraction in granulosa cells of rat preovulatory follicles. Biol Reprod, 2000, 62.. 895- 903.
  • 6Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidem Bio- mar, 2004, 13: 1185-1191.
  • 7潘其壮,覃展偶.uPA系统与肿瘤的研究进展[J].医学综述,2010,16(14):2140-2143. 被引量:8
  • 8Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res, 1999, 5: 3704- 3710.
  • 9Fishman DA, Liu Y, Ellerbroek SM, et al. Lysophosphatidic acid promotes matrix metallo proteinase (MMP) activation and MMP - dependent invasion in ovarian cancer cells. Cancer Res, 2001, 61: 3194-3199.
  • 10李毅亮,张兆辉,阮清源,邱利君,宋金春,汪宁,李慧.溶血磷脂酸对大鼠uPA蛋白的表达及其对血脑屏障的影响[J].卒中与神经疾病,2009,16(2):79-82. 被引量:5

二级参考文献35

共引文献11

同被引文献68

  • 1蔡昱,翟建军,段仙芝,何川,战媛,崔媛.子宫内膜癌术后10年生存因素的分析[J].实用癌症杂志,2014,29(3):301-303. 被引量:16
  • 2Sorosky JI. Endometrial cancer[J]. Obstet Gynecol, 2008, 111(1) :186-187.
  • 3Drapkin R,von Horsten HH,Lin Y,et al. Human epidid- ymis protein4 (HE4)is a secreted glycoprotein that is overexpressed by serous and dometrioid ovarian carcino- mas[J].Cancer Res,2005,65(6) :2162-2169.
  • 4Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action:critical new players in breast cancer initiation and progression[J]. Br J Cancer, 2010, 102 (6) : 941-946.
  • 5Bese T,Barbaros M,Baykara E,et al. Comparison of total plasma lysophosphatidic acid and serum CA125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2010,21 (4) :248-254.
  • 6Andersen MR,Golf BA,Lowe KA,et al. Use of a Symp- tom Index, CA125, and HE4 to predict ovarian cancer[J]. Gynecol Oncol, 2010,116 (3) : 378-383.
  • 7Hellstrm I, Raycraft J, Hayden-Ledbetter M, et al. The HE4(WFDC2) protein is a biomarker for ovarian carei- noma[J]. Cancer Res, 2003,63 (13) : 3695-3700.
  • 8Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer[J]. J Reprod Med,2005,50(8) :585-590.
  • 9Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometri- oid adenocarcinoma of the uterus [J].Gynecol Oncol, 2008,110(2) :196-201.
  • 10Wang FQ, Ariztia EV, Boyd LR, etal. Lysophosphatidic acid(LPA) effects on endometrial carcinoma in vitro pro- liferation,invasion, and matrix metalloproteinase activity [J]. Gynecol Oncol, 2010,117 ( 1 ): 88-95.

引证文献7

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部